Leadership

Esther Rawner is a board-certified neurologist and leader in drug development. She brings a wealth of experience and expertise to her role as Senior Vice President of Alkahest. She holds a Doctor of Medicine from New York Medical College and a Bachelor’s Degree in Biochemistry and Molecular Biology from Mills College. She completed her Medical Internship at Tulane University School of Medicine, her Neurology Residency at Yale University School of Medicine, followed by a Neurology Headache Fellowship at the University of Washington School of Medicine. Building and directing programs in clinical academia and successfully advancing and leading development programs in Biopharma, she has demonstrated visionary leadership and strategic aptitude in improving Neurologic care in academia and leading Drug Development at Grifols.

Scott Lohr has more than two decades of biotechnology experience with an emphasis on data management and analysis systems. His biotechnology journey started at Chiron, where he was on the cGMP manufacturing team for the multiple sclerosis drug Betaseron®. Scott then moved into bioinformatics as the field of functional genomics expanded and developed expertise in the area of data modeling of scientific workflows. Over the next two decades, he worked at large and small companies such as Genentech and Crescendo Bioscience, managing the storage, analysis, and distribution of data for in-house cancer genome projects to commercial diagnostics products. Scott received his Bachelor of Science in molecular biology and biochemistry from the University of California, Santa Cruz.

Benoit Lehallier, PhD, is head of data science at Alkahest Inc., where he uses cutting-edge proteomics to understand the cause of diseases and to identify new drug targets and early biomarkers of disease. Before joining Alkahest, Dr. Lehallier was a faculty member in the department of neurology at Stanford, where he led research on the molecular changes associated with normal and abnormal aging. Benoit’s research, featured in top scientific journals like Nature and covered extensively by mainstream media, has reshaped our understanding of the plasma proteome. Dr. Lehallier has more than 15 years of experience in industry and academia in integrating complex molecular signals in a systems biology context and has worked on dozens of cross-sectional and longitudinal cohorts.

Meghan Campbell obtained her Bachelor of Science degree in Physics from Georgetown University and completed her PhD in Molecular Biochemistry and Biophysics at Yale University. Following her graduate studies, Meghan moved to Genentech for a postdoctoral fellowship in Neuroscience. Over the last 15+ years, Meghan’s research has focused on understanding the molecular mechanisms underpinning a variety of diseases including Alzheimer’s, autism spectrum disorders, lupus, musculoskeletal disorders, acute liver injury, and peripheral neuropathies.

At Alkahest, Meghan leads a fantastic team of scientists working to fill the Grifols’ discovery pipeline with new therapeutics. She has supported development of novel technologies, IND filings, published three manuscripts, and even initiated the Alkahest run club. Outside of the office, Meghan is a mom of two young kids and enjoys hiking and spending time at beach near their home.